UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 1, 2007
AFFYMAX, INC.
(Exact name of registrant as specified in charter)
|
Delaware |
001-33213 |
77-0579396 |
|
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification No.) |
4001 Miranda Avenue
Palo Alto, California 94304
(Address of principal executive offices and zip code)
Registrant’s telephone number, including area code: (650) 812 -8700
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
o |
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
|
|
|
o |
|
Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12(b)) |
|
|
|
|
|
o |
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
|
|
|
o |
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
(b) On November 1, 2007, Affymax, Inc. (the “Company”) issued a press release announcing that Robert B. Naso, Ph.D., the Company’s Executive Vice President of Research and Development, plans to retire at the end of 2007. The Company plans to retain Dr. Naso as a consultant to advise on the strategic management of the Company. Dr. Naso’s direct reports, including Anne-Marie Duliege, M.D., M.S., Chief Medical Officer, Robert F. Venteicher, Ph.D., Vice President, Technical Operations and Peter R. Young, Ph.D., Vice President, Research, will report directly to Arlene M. Morris, President and Chief Executive Officer of the Company upon Dr. Naso’s retirement.
The press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Item 9.01. Financial Statement and Exhibits.
(d) Exhibits:
|
Exhibit No. |
|
Description |
|
99.1 |
|
Press Release entitled “Affymax® Announces Retirement Plans of Robert B. Naso, Ph.D. Executive Vice President, Research and Development”. |
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
|
|
AFFYMAX, INC. |
|
|
|
|
|
|
Dated: November 2, 2007 |
By: |
/s/ Grace U. Shin |
|
|
|
Grace U. Shin |
3
EXHIBIT INDEX
|
Exhibit No. |
|
Description |
|
99.1 |
|
Press Release entitled “Affymax® Announces Retirement Plans of Robert B. Naso, Ph.D. Executive Vice President, Research and Development”. |
4